Prostate cancer detection in the "grey area" of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun's nomogram, two risk estimators incorporating prostate cancer antigen 3.
Detection of TMPRSS2 ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
In February, the FDA approved an assay for another prostate cancer biomarker, prostate cancer antigen 3
(PCA3), a gene that is specific to prostate cancer and, unlike PSA, is not increased by non-cancerous conditions.
Other tests augment the PSA, including PSA velocity (the rate at which PSA rises over time), as well as the new prostate cancer antigen 3
(PCA3) test, which measures a gene specific to prostate cancer.